Clinuvel Pharmaceuticals Value Stock - Dividend - Research Selection
Market price: 27,37 AUD
Clinuvel Pharmaceuticals Fundamental data and company key figures of the share
|Annual reports in AUD|
|Net operating cash flow||14.188.000|
|Free cash flow||13.299.542|
|Liabilities & Shareholders equity||82.000.000|
|Diluted shares outstanding||50.458.000|
✓ NEW Fundamental API Access to 500 data points per month
✓ Fundamental data up to 25 years
✓ Comparison to all other stocks by the FScore
✓ Time saving!
How our site works ...
✓ Non-binding 7 days without automatic subscription
✓ No termination required after the free week
✓ Finanzoo fundamental analysis
✓ Data updated daily
✓ Virtual depots
✓ Share alarms via email
✓ Subscription can be canceled at any time at the end of the month
✓ Choice of desired shares
✓ Over 2000 stock analyzes available
✓ Bitcoin payment possible if you do not want to subscribe
Price for monthly subscription $ 19.99 / month including VAT.
|Market Capitalization||1.060.051.776,00 USD|
|Raw Data Source||IFRS in Millionen AUD|
Description of the company
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing drugs for the treatment of severe skin disorders in Europe and Switzerland. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria that has completed Phase II and III trials in the United States and Europe. The company\'s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and VLRX001, an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity. Clinuvel Pharmaceuticals Limited was incorporated in 1999 and is headquartered in Melbourne, Australia.